Study finds promising first evidence of targeted therapy for NRAS-mutant melanoma

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

Why Aphthous Ulcers Are More Than Just Canker Sores

For clinicians, managing recurrent aphthous stomatitis means looking beyond the ulcer to triggers and systemic links.
Worcester Telegram

WPI resident advisors are on strike: Here's why

WORCESTER – Resident advisors at Worcester Polytechnic Institute have gone on strike, leaving the university without a ...

Revolution Medicines a new outperform at RBC on RAS(ON) inhibitors for cancers

RBC Capital Markets has initiated Revolution Medicines (RVMD) at outperform, saying that its platform of "RAS(ON)" inhibitors to treat various cancers has demonstrated strong efficacy thus far. The ...

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

We are gratified the FDA has granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer, a devastating disease with limited therapeutic options and representing a large ...
News-Medical.Net on MSN

Breakthrough research offers first targeted treatment option for NRAS-mutant melanoma

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...
Healio

GLP-1s may double risk for development of wet AMD

Use of GLP-1 receptor agonists was associated with a twofold higher risk for neovascular age-related macular degeneration ...
EurekAlert!

Moffitt study finds promising first evidence of targeted therapy for NRAS-mutant melanoma

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients ...